Literature DB >> 8518176

Summarizing data on survival, relapse, and chronic graft-versus-host disease after bone marrow transplantation: motivation for and description of new methods.

M S Pepe1, G Longton, M Pettinger, M Mori, L D Fisher, R Storb.   

Abstract

Kaplan-Meier curves are frequently used to summarize survival, relapse, and chronic graft-versus-host disease (GVHD) data in the bone marrow transplant setting. Some fundamental problems with the use of Kaplan-Meier curves for the summary of relapse and GVHD are described. Alternatively, the use of simple probability and conditional probability curves for summarizing relapse incidence and transplant-related mortality is illustrated with previously published data from a randomized clinical trial. Prevalence curves provide an appropriate alternative for the summary of a transient condition such as chronic GVHD. When combined with Kaplan-Meier curves for survival and/or relapse-free survival, these methods provide a more accurate and comprehensive summary of the various marrow transplant outcomes. These methods of display are also applicable to other settings where more than one type of treatment failure can occur and where follow-up time may be variable.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8518176     DOI: 10.1111/j.1365-2141.1993.tb04697.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  6 in total

1.  Zoledronic acid boosts γδ T-cell activity in children receiving αβ+ T and CD19+ cell-depleted grafts from an HLA-haplo-identical donor.

Authors:  A Bertaina; A Zorzoli; A Petretto; G Barbarito; E Inglese; P Merli; C Lavarello; L P Brescia; B De Angelis; G Tripodi; L Moretta; F Locatelli; I Airoldi
Journal:  Oncoimmunology       Date:  2016-09-27       Impact factor: 8.110

2.  Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation.

Authors:  Steven Z Pavletic; Shelly L Carter; Nancy A Kernan; Jean Henslee-Downey; Adam M Mendizabal; Esperanza Papadopoulos; Roger Gingrich; James Casper; Saul Yanovich; Daniel Weisdorf
Journal:  Blood       Date:  2005-07-26       Impact factor: 22.113

3.  Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study.

Authors:  C Madsen; M R Clausen; T L Plesner; A Pasanen; T Kuismanen; H H Bentzen; J M Jørgensen; I B Sillesen; B M Himmelstrup; D Rønnov-Jessen; K R Jensen; A M Pettinger; M Ludvigsen; S Leppä; F A d'Amore
Journal:  Blood Adv       Date:  2018-07-10

4.  Allogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia.

Authors:  Jean E Sanders; Ho Joon Im; Paul A Hoffmeister; Ted A Gooley; Ann E Woolfrey; Paul A Carpenter; Robert G Andrews; Eileen M Bryant; Frederick R Appelbaum
Journal:  Blood       Date:  2005-01-06       Impact factor: 22.113

5.  A Brief Introduction to Competing Risks in the Context of Kidney Disease Epidemiology.

Authors:  Nicholas S Roetker; David T Gilbertson; Eric D Weinhandl
Journal:  Kidney360       Date:  2022-02-17

6.  Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.

Authors:  Mohamed L Sorror; Barry E Storer; Brenda M Sandmaier; Michael Maris; Judith Shizuru; Richard Maziarz; Edward Agura; Thomas R Chauncey; Michael A Pulsipher; Peter A McSweeney; James C Wade; Benedetto Bruno; Amelia Langston; Jerald Radich; Dietger Niederwieser; Karl G Blume; Rainer Storb; David G Maloney
Journal:  J Clin Oncol       Date:  2008-09-15       Impact factor: 44.544

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.